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Human Neuroblastoma Cell Lines as Models
for the In Vitro Study of Neoplastic and
Neuronal Cell Differentiation
by Elliot Abemayor* and Neil Sidellt
Neuroblastoma is a childhood solid tumor composed ofprimitive cells derived from precursors ofthe au-
tonomic nervous system. This neoplasm has the highest rate ofspontaneous regression ofall cancer types
andhas been noted toundergo spontaneous andchemically induceddifferentiation intoelements resembling
mature nervous tissue. As such, neuroblastoma has been aprime model system forthe studyofneuronal dif-
ferentiation and the process ofcancer cell maturation. In this paper we review those agents that have been
described to induce the differentiation ofneuroblastoma, with an emphasis on the effects andpossible mechan-
isms ofaction ofa group ofrelated compounds, the retinoids. With this model system and the availability
ofsubclones that are both responsive and resistant to chemically induced differentiation, fundamental ques-
tions regarding the mechanisms and processes underlying cell maturation have become more amenable to
in vitro study.
Introduction
Neuroblastoma (NB) is a common childhood solid tumor
ofthe autonomic nervous system with a yearly incidence
of 8.7/1 million children. Stated differently, the disease
represents 7% ofthe total cases ofchildhood cancerdiag-
nosed annually with the tumor developing in approxi-
mately one in 7000 children before the age of5 years and
an average of525 newly diagnosed cases inthe U.S in any
given year (1). The most widely used clinical staging sys-
tem was devised on the basis of the size of the primary
tumor and the degree and sites of dissemination. Using
this scheme, it has been noted that the tumorhas spread
beyond the organ oforiginbythe time itis first diagnosed
in up to 55% ofpatients, thereby seriouslyworseningtheir
prognosis (1). The histology ofmost NB includes a small
primitive cell component with avariable number ofmore
mature neural or ganglion cells (2). Although Beckwith
and Martin (3) reported that more differentiated ne-
oplasms were less aggressive, other investigators (4,5)
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have notfound that a simple relationship exists between
the degree of cell differentiation and clinical prognosis.
Given the degree of widespread disease in NB and the
poor response to conventional therapies, more novel ap-
proaches to treatment have been sought.
In 1927, CushingandWolbach (6)firstreported the sin-
gular phenomenon ofspontaneous differentiation of NB
to a benign ganglioneuroma. More detailed analysis of
casesexhibitingspontaneous tumorregression showsthat
thisphenomenon occurs with minimal or no therapy in a
subgroup ofinfants designated ashaving stage II or IVS
disease (7). Surprisingly, disease regression may be seen
with or without maturation of tumor elements and pro-
gression mayoccurdespite thepresence oflarge areas of
histological maturation in the specimen (8). Ofinterest is
the fact that stage IVS patients, with metastases in the
liver, skin, andbone marrow, have almost a 70% survival
rate withminimal therapy(2,8). These observations, that
a smallproportion oftumors ceaseproliferatingand even
undergo spontaneous maturation, prompted interest in
the study ofNB as amodelforthegeneralprocess oftu-
mor cell differentiation, as well as neuronal development.
This paper will review some ofthe current data avail-
able on the in vitro differentiation of human neuro-
blastoma cell lines. The usefulness ofthese cell lines for
the general study ofquestions related to differentiation
will be examined. In addition, we will propose several
novel mechanisms ofactionforvarious agentsused to in-ABEMAYOR AND SIDELL
duce in vitro differentiation, in particular, new develop-
ments from the authors' laboratory concerning retinoid
compounds will be given special emphasis. Where the
mechanism(s) ofaction inneuroblastoma hasnotbeen in-
vestigated, workfromothercultured cell systemswill be
presented. No attemptwillbemade to reviewthe entire
field ofneuronal differentiation norofthe differentiation
of cell lines derived from nonhuman species, as this has
recently been discussed (9,10). For an in-depth compila-
tion ofwell-characterized human NB celllines, see the re-
view by Bottenstein (9). More recently characterized cell
lineswillbe discussedunderthe pertinent sections deal-
ing with agent-induced differentiation (vide infra).
Development and Differentiation of
Human Neuroblastoma Cell Lines
Addressingfundamental questions concerning the cel-
lular and molecular events controlling neural differenti-
ation have been hampered by the lack ofnormal diploid,
continuously dividing neuroblasts or their precursors.
This factor has led to the use of cell lines derived from
spontaneously arising tumors as sources ofneuronal-like
cells in various stages ofdevelopment. Sundry cell lines
have been developed that exhibit numerous characteris-
tics ofprimitive and differentiated neurons and, despite
theiraneuploidy and obscure pedigree, haveproven use-
ful inthe study ofneural development. Whereas mostmu-
rine neuroblastoma cell lines wvere derived from a single
aneuploid tumor(9), manyhumanneuroblastomacelllines
havebeengeneratedfromavarietyofperipheralnervous
system neoplasms. Current evidence suggeststhatthese
tumors arise from cells containing characteristics ofau-
tonomic, adrenergic, or cholinergic neuroblasts (2). That
these tumors are composed ofa heterogenous cell popu-
lation is demonstrable by studying cell-surface antigens
(11), catecholamine metabolites (12), and neurotrans-
mitter-synthesizing enzymes (13). Thisheterogeneity has
beenfurtherappreciatedby studyingsubcloneswithin es-
tablished cell lines(2,13). Such dissimilarity within seem-
inglyuniform tumors hasmajorimplications fortherapeu-
tic interventions as well as basic in vitro studies.
In investigating the process ofdifferentiation, the first
question thatneeds to be addressed is how does onebest
assess the process. The most commonly measured charc-
teristic of differentiation has been neurite extension. A
neurite is defined as a process whose length equals or
exceeds the cell body diameter (9). These processes are
akin to the axonsand dendrites offully differentiated neu-
rons and can appear hours to days after the induction of
the putative differentiated state (Fig. 1). Unfortunately,
unlike the situation in some other cell systems, suitable
criteria for determiningvery early stages ofcell differen-
tiation are lacking in NB. Forexample, differentiation of
the HL-60 promyelocytic leukemic cell line is most eas-
ily appraised by monitoring the cells' ability to reduce
nitroblue tetrazolium, a property that is acquired prior
to any obvious morphologic alterations; thispermitsrapid
monitoring of the differentiated state (14). In NB, such
convenient early markers have not been defined, thus
hampering detection ofthe initial stages ofcommitment
to a differentiatedphenotype andforcinginvestigators to
rely eitheronmorphologic changes alone or onbiochem-
ical modulations (eg., neurotransmitter synthesis)that ac-
companyratherthan control differentiation. However, re-
cent developments in the detection ofvarious oncogenes
in human NB cells now present the possibility of study-
ing the regulation ofgenes that are directly involved in
early stages of the differentiation process (see "On-
cogenes").
Both intivo andinvitro NB cells, as derivatives ofneu-
ral crest origin, are known to havethe capacityto express
multiple phenotypes, including neuronal, neurilemmal
(Schwann), and melanocytic characteristics (15-24). This
heterogeneity is observed despite the fact that the cells
are presumably derivedfrom common neuroblast progen-
itorcells(23). Acompellingbodyofevidencehasbeenpre-
sentedby Biedler andherassociates(15-17,20,22) that as-
sists in clarifying the nature of this tumor cell mixture
with the potentialfor coordinate biochemical andmorpho-
logic interconversion. This work has been extended in a
recent study(23)wheretheinvitro differentiation offive
human NB cell lines treatedwith cAMP and RA was ex-
amined. Three overallmorphologic phenotypes were ob-
served: neuronal, characterizedby cell processes and neu-
rosecretorygranules; flat, nonpigmented cells displaying
the characteristics ofSchwann cells; and flat, pigmented
cells displaying the characteristics ofmelanocytes. Simi-
larly, it hasbeen shown that two neuroblastoma variants
derivedfrom a commonprecursor cell can have dramati-
cally different responses to asingle differentiating agent
(24), withone undergoingneuronal-like differentiation and
the other transformed into large, flattened Schwannlike
cells. Whereas itis currentlyunknownwhichgenetic and
epigenetic controls determine the particular path and
characteristics chosen on assuming the differentiated
state, these investigations emphasize the factthatneuro-
blastoma cells represent an early stage inneuronal devel-
opmentwhere the cells arepluripotent, andretainthe ca-
pabilities for expressing multiple neural crest-derived
phenotypes. This knowledge makes clear the potential
risksinevaluatingagentsthatinduce differentiation ifone
only assesses neuronal maturation and ignores the pos-
sibility that the cell maybe committed to a Schwann cell
or melanocytic pathway.
Oncogenes
Recentprogress in theunderstanding ofcancerhasfo-
cused on the role of cellular genes, termed "protoon-
cogenes" oroncogenes, that can induce tumorgrowth in
humans. The principal ways by which oncogenic activa-
tion takes place are pointmutations, chromosomal activa-
tionandoncogene amplification(25-27). Sporadic amplifi-
cations of the oncogene c-myc were first noted in the
promyelocytic cell line HL-60(28) and in colon carcinoma
cells containing double minute chromatin bodies (DMs)
and long, nonbandinghomogeneously stainingregions of
chromosomes (HSRs) (29). These findings prompted a
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FIGURE 1. Differentiation ofhuman neuroblastoma cells by retinoic acid. (A) Solvent-treated control culture of LA-N-5 human neuroblastoma cells.
Very few neurites have extended from these loose aggregates of cells. (B) Scanning electron micrograph of 16-day retinoic acid-treated LA-N-5
cells showing the bundlingpatterns ofindividual nerve fibers, x 8000. (C) Cells cultured in the presence of 3 x 10- 6 M retinoic acid for 16 days.
Dense cellular aggregates have formed and many neurites have grouped to form thick fascicles, x 250.
A
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search for nonsporadic amplifications in NB, as DMs and
HSRs have both been described in primary NB tumors
and cultured cell lines (30,31). This exploration resulted
in the discovery ofmultiple copies ofagene with partial
homology to the c-myc oncogene localized by in situ
hybridization techniques to the DMs and HSRs of NB
cells (27). The expression ofthis gene, called N-myc, has
been detected in only a small number ofcancer cell types
including NB, retinoblastoma (32), small-cell lung carci-
nomas (33), and embryonal carcinoma cell lines (34). In ad-
dition, appreciable N-myc mRNA elevation has been
shown in fetal neural cells with areduced expression oc-
curring during cellular differentiation (35).
Unlike the ras oncogenes, no mutations are required for
N-myc activation, thus focusing attention on quantitative
differences in expression between tumorandnormal cells
(26,27). Several lines of evidence suggest that N-myc
amplification and expression are related to the malignant
potential ofNB tumors andto cellgrowth in'vitro. Ampli-
fication is correlated with advanced pathologic staging of
the disease, a predominance of undifferentiated tumor
histology, and an enhanced capacity for the cells to form
continouslygrowing cell lines (36-38). There is also aposi-
tive correlation between genomic amplification andtumor
progression that is independent ofthe extent ofinitial dis-
ease (36-38). The amplified N-myc copy number is con-
sistent within atumor, at different tumor sites, and at dif-
ferent times during the course of the patient's disease
(38). In addition, the majority ofNB cell lines contain am-
plified copies ofN-myc, although afew, e.g., the SK-N-SH
line, do not. The latter line contains a mutationally acti-
vated dominantgene, N-ras, whichisnot specificfor NB
and is found amplified in some other tumors (39,40). The
role ofN-myc as aprotooncogene capable ofinflicting cell
transformation without the need to cooperate with other
oncogenes has been demonstratedby Small etal. (41)who
have shownthatit can actalone toelicitneoplasticgrowth
ofan established line ofratfibroblasts. Since the primary
function ofthe mycprotein itselfis not known, itremains
unclearas tohow elevations in N-mycexpression enhance
tumor cell transformation and growth.
It has been shownin several NB cell lines that differen-
tiation results in a reduction in cellular N-myc mRNA
content with no change in genome amplification (42,43).
Inthe NB cellline SMS-KCNR, decreased N-myc expres-
sion was detected within 6 hr oftreatment with retinoic
acid (RA) and preceded both cell-cycle changes and
morphological differentiation (43). This down-regulation
of N-myc expression could result from decreased tran-
scription or from changes in the turnover of mRNA; a
choicebetweenthese alternativesin NB is currently not
possible. However, in teratocarcinoma cells, treatment
with retinoic acid results in a 50% reduction in the level
ofc-mycmRNAwithin3 hraftertreatment(44)possibly
as aresult ofposttranscriptional regulation mechanisms
affecting the short half-life of the c-myc transcript (45).
Recently, rabbit antiserahasbeenproducedthatspecifi-
callyrecognizes a62 to64 kDfragment ofthe N-mycpro-
teinproduct(46). As seeninFigure2, nucleiofuntreated
LA-N-5 neuroblastoma cells stongly react with the anti-
N-myc serawhile those ofRA-treated LA-N-5cells show
little, ifany, reactivity. Using this antisera, we have ob-
served reduced staining ofLA-N-5 cells afteronly 4 to 6
hr treatment with RA, which is consistent with similar
rapid decreases in N-myc mRNA. These results demon-
strate that expression of oncogenes in NB can be modi-
fiedby differentiating agents andoncogeneregulation can
occur prior to morphological modifications.
TherecentworkbyThiele etal. (47), aswellasthework
in our laboratory (48) has permitted detection of tran-
scripts ofavarietyofotherwell-characterized oncogenes.
As seen in Table 1, the majority ofthose oncogenes de-
tected show altered expression during RA-induced
differentiation. Some ofthese(N-myc, c-myb, H-ras, c-erb)
A B
FIGURE 2. Immunoperoxidase staining of LA-N-5 neuroblastoma cells with antibody against the N-myc protein product. Cells were grown in the
absence (A) orpresence (B) ofretinoic acid(2 x 10 -6M)for3 days, then prepared and stained accordingto the method ofSlamon et al. (46). Cells
were not counterstained; therefore, all staining was due to the reaction between the primary antiserum and N-myc proteins.
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Table 1. Effects of retinoic acid-induced different on oncogene
mRNA levels in human neuroblastoma cell lines.a
Oncogene mRNA level Time
N-myc 1 3 hrb, 2-4 daysc
c-myb 4 3 hr, 2-4 days
H-ras a 3 hr, 2-4 days
N-ras, K-ras NCd
c-fos t 48 hr, 8 days
cets-1 t 48 hr, 4 days
c-erb t4 0.25 hr, 4 days'
p53 1 48 hr, 6-7 days
c-myc, c-cis ND'
aSMS-KCNR and LA-N-5 cell lines were used in these studies. Data
forp53 arefrom Sidell andKoeffiler(48). Allotherresults arefromThiele
and Israel (unpublished data).
bTreatment time to detect initial changes in mRNA levels.
cTreatment time for showing maximal changes in mRNA levels.
dNC, no change.
eInitial increase, then not detected at 4 days.
fND, not detected.
show changes that temporally precede any detectable
morphologic or biochemical changes and may therefore
play aprimary role in the differentiation process. In sum-
mary, it appears that oncogenes play an important role in
thegrowth andmalignantpotential ofNB cells, and some
are regulated during differentiation. With the availabil-
ity of antisera to oncogene-encoded proteins (46), the
potential for monitoring early events associated with
differentiation andfordeterminingtheroleoftheproteins
in this process will become feasible.
Macara (49) has proposed that certain oncogenes may
be regulated by alterations in cellular ionic signals (e.g.,
Na, H, Ca), which in turn induce further changes in on-
cogene expression andcellreplication anddifferentiation.
This coupling ofchanges in cellular ionic milieu with al-
terations in oncogenes and differentiation hasbeenborne
out in some cell systems using various agents. Morgan
and Curran(50) described induction ofthe oncogenec-fos
in the pheochromocytoma cellline PC12 with agents that
affect voltage-dependent Cachannels. Intheleukemic cell
line HL-60, and in murine erythroleukemia cells (MEL),
alterations in Na-H exchange, increases in voltage-
activated Kcurrent, andchanges in intracellular Ca con-
centrations havebeenobservedaccompanyingchemically
induced cell maturation (51-55). In murine NB celllines,
the K ionophore valinomycin (55) and high levels of ex-
tracellular Ca(56) have been shown to cause neurite ex-
tension. Hence, althoughhighly speculative atpresent, it
isplausible that induced differentiation in NBmay inpart
be triggered by perturbations in the ionic environment.
This possibility is more fully explored below in discuss-
ing the mechanism(s) of action ofretinoids on NB.
Retinoic Acid and Derivatives
Retinoids are aclass ofnatural and synthetic analogues
ofretinolthathavelongbeenknowntohavepotenteffects
on cellproliferation and differentiation. In 1925, Wollbach
and Howe (57)noted that vitamin Adeficiency in the rat
resulted in a failure of stem cells to properly differenti-
ate into mature epithelial cells accompaniedby an abnor-
mal differentiation ofthepreexisting epithelial cells. Since
then, anextensivebodyofliterature hasgrowndocument-
ingthe invtivoandinvitro effects ofretinoids in suppress-
ingthe development ofthe malignant phenotype (58-60).
These effects are visible after short-term culture with
nanomolar concentrations ofretinoids. Since the physio-
logical serum concentration ofvitamin A metabolites are
in the nanomolar range, and micromolar levels can be
achieved pharmacologically, these effects are ofbiologi-
cal significance.
As a group, human NB cell lines are extremely sensi-
tive to retinoic acid (RA)-induced growth inhibition and
phenotypic changes (24,61-63). However, despite an abun-
dance of work describing the morphologic changes in-
duced by RA in NB, there is a dearth ofmechanistic de-
tail. Although RA can inhibit the growth, reduce colony
formation in soft agar, and induce morphologic differen-
tiation of a host of human neuroblastoma cell lines, a
neuronal-like differentiation effectisnotuniversal. Forex-
ample, RA treatment of a subline of SK-N-SH does not
cause neurite extension, but instead yields large fibro-
blastic epithelial-like cells (24,62). This effect may in part
reflect thefact thatthis cellline contains some cells capa-
ble ofexpressingamelanocyticphenotype (22,23,64). In-
deed, the differentiation ofneuroblastoma cells within a
single line need not always result in neurite sprouting
since many lines are composed ofheterogenous cell ele-
ments with different phenotypic potential (21,22,65).
In order to first assess thepotential clinical applications
and limitations ofRAtreatment ofNB inhumans, anude
mouse model system was established by the present
authors. First, we testedthe effects ofinvitro treatment
with RA on the tumorigenic potential of NB cells as
judged by measurement of gross tumor formation. As
shown in Figure 3, there was a marked reduction in the
number oftumors in mice injected with LA-N-5 cells that
had previously been treated in vitro with RA. In those
tumorsthatdid develop, nomajordifferences were noted
in the average size between the two groups nor in the
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FIGURE 3. Tumor development in nude mice after injection ofin vitro-
treated LA-N-5 neuroblastoma cells in two separate experiments
(A,B). Cells (107) were injected (SC) after being cultured in the ab-
sence (0) or continuous presence (0) of4 x 10-6 M RA for 18 days.
Tumor development was recorded onthe day that anodule couldfirst
be definitively detected (,- 3-5 mm diameter).ABEMAYOR AND SIDELL
histologic appearance ofthe tumors. The establishment
of tumors in some mice receiving RA-treated cells may
have resulted from the outgrowth of a subpopulation of
cells resistant to RA, aphenomenon that has previously
been described in vitro (65).
In a different series ofexperiments, long-term in vivo
treatment of mice with RA at doses achieving serum
levels of 1-2 x 10-6 M resulted in a reduction ofthe per-
centage of mice that developed tumors as compared to
solvent-treated controls (Fig. 4). In a similar vein, RA
treatment of mice with established neoplasms substan-
tially reduced the growth rate ofthe tumors (Fig. 5). In-
deed, while the tumors continued to progressively grow
over the entire treatment period in the control group,
there was little growth in tumor size in the RA-treated
group after the first 2 weeks of dosing. Histological ex-
amination ofselected specimens by H & E and Bielschow-
sky staining revealed no major morphologic differences
in tumors obtained from the two treatment groups al-
though, as was expected from their slower growth rate,
a reduced number of mitotic figures was apparent in
tumors obtained from RA-treated animals. Thus, although
systemic administration ofRA resulted in aplateauing of
tumorgrowth, there was noobviousmorphologic differen-
tiation as evidenced by neurite formation similar to that
observed with invitro-treated cells. Thisfinding does not
exclude thepossibility thatother, more subtlechanges are
occuringthat are consistent with neuronal differentiation,
such as a reduction in N-myc gene expression (Fig. 2).
Thken together, these dataindicate that RAhas a signifi-
cant role in diminishing the malignant phenotype of in
vitro-treated NB tumors, or as abiological modifier once
the tumor has been implanted.
Cellular Retinoid-Binding Proteins
Because ofits lipophilic nature, the transport ofretinol
and RA requires specific binding proteins. Two ofthese
proteins, cellular retinol-binding protein (CRBP) and cel-
lular retinoic acid-binding protein (CRABP) are ubiqui-
tous, not tissue specific, and are located in the cytosol of
cells(60), although plasma membrane-bound CRABP has
also been described (66). By analogy to steroid hormones,
it has been proposed (67) that the retinoid binding pro-
teins translocate retinoids to the cell nucleus where they
exert an effect on chromatin and gene expression. Al-
though current evidence supports the viewthatretinoids
are capable ofbeingtransported tothe nucleus viaCRBP
and CRABP(67), direct evidenceforthe role ofthesepro-
teins in exclusively mediating the actions ofretinoids is
lacking. For example, in embryonal carcinoma cell lines,
CRABP appears tobenecessarybut not sufficientforthe
induction of differentiation (68,69). Matthaei et al. (70)
have reported that cells from several human embryonal
carcinomalines possess highlevels ofCRABPbutfail to
undergo differentiation in the presence of RA. Con-
versely, in the HL-60 cellline no bindingactivityhasbeen
detected, althoughthecells are very sensitive to differen-
tiation by RA (71).
Haussler et al. (72) have shown that there is a lack of
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FIGURE 4. Development ofLA-N-5 tumors in in vivo-treated nude mice.
Four- to six-week-old nude mice were dosed daily with 0.1 mL of
4 x 10-3M RA PO (in corn oil) (0) or solvent control (0) starting 5
days before injection (SC) of 107 LA-N-5 cells and continuing for 14
days afterinjection ofthe cells. Themice were examined twiceweekly
fortumordevelopment, which was recorded on the day that apalpa-
ble nodule could first be detected (\ 3-5 mm in diameter).
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FIGURE 5. Growth ofestablished LA-N-5 tumors in invivo-treated nude
mice. Mice were treated daily for 32 days with either 0.1 mL of4 x
10-3M RA PO (in corn oil) or solvent control after development of
roughly 1-cm diameter nodules. The tumors were measured once or
twice a week. The points represent the mean tumor volume (± SE)
measured in the control (0) (5 mice) and RA-treated groups (0) (6
mice).
8DIFFERENTIATION OF NEUROBLASTOMA
strict correlation between RA-induced anchorage-
dependent growth and CRABP levels in human NB cell
lines. Correspondingly, there is avariable relationship be-
tween retinol-induced cell differentiation andlevels ofas-
sayable CRBP activiy (73). In afurther effortto ascertain
the role ofthese bindingproteins inthe mechanism ofac-
tion ofretinoids, Jetten et al. (74) compared the biologi-
cal activity of several newly synthesized benzoic acid
derivatives with their binding capacity to CRABP.
Whereas some ofthe compounds exhibited high biologi-
cal activity, they did notbind to CRABP. Fromthese and
other data, it appears unlikely that retinoid-induced cell
differentiation is brought about solely by the interactions
ofthe bindingprotein-retinoid complex with nuclear chro-
matin.
RA and Protein Kinase Activity
The role ofprotein phosphorylation in modulating cell
growth and differentiation has been actively investigated,
particularly with reference to changes in the cAMP-
dependent kinase system, the Ca-dependent protein kin-
ase C (PKC), and the oncogene-derived protein kinases
(75-77). Consequently, interest in the actions of RA on
these systems has grown.
Plet et al. (78) have shown that RA treatment of
differentiation-responsive embryonal carcinoma cells
caused an increase inthe cytosolic andplasmamembrane-
bound cAMP-dependent kinases with a preferential in-
crease inthe RII regulatory subunitassociated with the
membrane fraction. It should be noted, however, that
some investigators were unable to demonstrated changes
in cAMP-dependent protein kinase activity upon treating
embryonal carcinoma cells with RA (69).
Retinoid treatment has also been reported to enhance
protein kinase activity in HL-60 and melanoma cells
(79,80). In HL-60 cells and in the myeloblast cell line
RDFD, there is also a direct correlation between the de-
gree of cell differentiation and elevation in cAMP-
dependent protein kinase activity, as well as an increase
in the phosphorylation of various specific substrates of
this enzyme (81). Ib our knowledge, studies directly as-
sayingchanges in cAMP-dependent protein kinase in RA-
treated NB cell lines have not yet been reported. Given
the responsiveness ofthese lines to RA and cAMP and
the availibility of subclones that are relatively resistant
to these agents (65), it would be ofinterest to study the
role that this kinase system plays in the differentiation
phenomenon. From studies in othercell systems, itwould
be fair to conclude thatretinoids may exert some oftheir
effects in NB bymodulation ofcAMP-dependentprotein
kinase activity or enzyme levels.
In addition to the cAMP-dependent kinase, the CA-
dependent PKC has been shown to be important in the
differentiation process. This membrane-bound kinase,
originally identifled in brain (82) is widely distributed in
cells, appears to be the target for the tumor promoting
phorbol esters, and is important in the control of signal
transduction and tumor differentiation (83). In myeloid
precursors, there is a stimulation ofPKC enzyme activ-
ity andphosphorylation ofits various substrates correlat-
ing with RA-induced differentiation (81) occurring prior
to the commitment of the cells to the myeloid pathway
(84). In contrast, embryonal carcinomacells exhibitan in-
crease in PKC activitythat accompaniesbut does notpre-
cede differentiation (85), suggesting that in the latter sys-
tem, these effects may be a consequence rather than a
cause ofdifferentiation. In othertissues, dependingon the
assay conditions, retinoids have been reported to have a
stimulatory and an inhibitory effect (86), solely an inhibi-
tory effect(87), orno effect at all(88)onthe Ca-dependent
kinase system. These disparate observationspreclude any
facile inferences asto how RAmayact on PKC in NB and
whether this has any primary effect on NB differentia-
tion.
RA Effects on Ion Channels
Since changes in cation transport across the plasma
membrane have beenimplicated as controllingfactors in
the regulation of cell growth and differentiation (vide
supra), we have been interested in the prospect that RA-
induced differentiationofNB cellsispartlytriggeredby
alteration ofionchannel activityintheplasmamembrane.
lt was first demonstrated that RA can alter membrane
ion-channel activity in mammalian cells by showing that
itblocks Kchannels inhumanlymphocytes andthat this
activity canaccountforsome ofitsimmunomodulating ef-
fects(89,90). Because the Kchannelsinthese cells are un-
usualinthatthey are sensitive toboth Kchannelblockers
and to some classical Ca channel blockers (91), we have
further investigated the specificity of RA blockage in
other cell types. As seen in Figure 6, RA blocks T-type
Ca channels in a mouse hybridoma cell line (92,93) but
does not affect the K channels in human neuroblastoma
cells(which areinsensitive to Ca-channelblockers). Thus,
the effects ofRA on humanlymphocyte K channels may
in part be the result of an interaction with components
that are shared with Ca channels, as reflected inthe sen-
sitivity of these K channels to blockage by Ca channel
blockers. In the mouse hybridoma cells, the dose-
dependent effects of RA on Ca channels correlate with
the ability ofthis compound to inhibit cell proliferation,
FIGURE 6. Retinoic acid reduces the inward Ca current in MHY206 mu-
rine hybtidoma cells. Usingthe whole-cell patch clamp technique(146),
currents were measured during a voltage pulse from a holdingpoten-
tial of -80mV to -20mV. The figure shows the Ca current through
T-type Ca channels (147) recorded before (control) or 5 min after 5 x
10- M RA had been added to the bath solution. The channel block
by RA was reversible such that afterwashout, the currents were very
close to control values (not shown).
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Table 2. Blockage of ion channels and biological action ofretinoic acid on different cell types.
Channel type Dose (M) for 50% maximum effect
Cells studied Channel block Biological response'
T-lymphocytes (human) K 2.5 x 10 3 x 10-5
Natural killer (human) K 2.5 x 10i 5 x 10-5
206 (mouse B-cell hybridoma) Ca (T-type) 5 x 10-5 3 x 10-5
GH3 (rat pituitary cells) Ca (T-type) Nob No
Ca (L-type) No
LA-N-5 (human neuroblastoma) K No
Ca(??)c <10-6 - 7
aEffect of RA on T-lymphocytes (89) and 206 cells (92) is antiproliferative at the doses shown; its effect on natural killer cells is to inhibit killing
(89); on LA-N-5 cells RA induces differentiation (62).
bl0-4 M RA was the highest concentration tested and showed no effects.
cThe exact ion selectivity and dose range for channel block have not yet been characterized.
suggesting that blockage ofthe channels contributes to
its antiproliferative activity(92). In contrast tothe notion
that RA's effects on Cachannels are nonspecific is ourun-
published observation that RAhas no effect on Ca chan-
nels inthe ratpituitary cellline GH3 (which contains both
T-type Ca channels like those in the hybridoma cells and
L-type Ca channels) (94) and does not inhibit theprolifer-
ation ofthese cells. Thus, the ability of RA to modulate
ion-channel activity, and perhaps to ultimately induce a
biological response, may in part be dependent not only
uponchanneltypebutalso onthepresence ofspecific RA-
sensitive receptors or components that can influence
channelfunction. As seen in Table 2, preliminary experi-
ments suggest that RA canalso block Cacurrents inneu-
roblastoma cells, and atlowerconcentrations (< 10 -6M)
than seen inthe other cells (1-5 x 10-5 M). Thisparallels
the substantially greater sensitivity of neuroblastoma
cells to the biological action of RA.
Although it is difficult atthispoint to hypothesize how
blocking Ca channels by RA might contribute to the dif-
ferentiation of neuroblastoma cells, recently acquired
knowledge ofthe second messengerfunctions ofCacould
serve as a point of departure for future studies. For ex-
ample, PKC activity is regulated both by the amount of
activated C-kinase bound to theplasmamembrane andby
the rate ofCa cycling across this membrane (77). Thus,
an RA-induced block of Ca influx through Ca channels
could theoreticallylead to an inhibition ofC-kinase activ-
ity with subsequent modification of a variety of cellular
process dependent on this phosphorylating enzyme. This
hypothesis is consistent with results in some other sys-
tems where RA hasbeen shown to decrease C-kinase ac-
tivity (87)albeit notuniversally (86,88). Anotherpossible
consequence ofblocking Ca channels with RAthat could
involve the phosphatidylinositol-mediated second mes-
senger system is inhibiting a membrane depolarization
that is necessary during cellgrowth(95). Clarification of
a general role for ion-channel modulation in the biologi-
cal action ofRA will require future characterization and
correlation ofthese activities in avariety ofcell systems.
Other Differentiating Agents
Nerve Growth Factor
IfNB cells are considered tobetheneoplastic counter-
parts ofsympathetic neuroblasts, then nervegrowthfac-
tor(NGF)wouldbe regarded as alikelytriggeringagent
for differentiation (96,97). With little experimental data,
this rationale prompted an early clinical trial in children
with metastatic neuroblastomawhere NGF wasgiven to
promote tumor cell maturation and retard malignant
growth; disappointingly, the clinical course was not af-
fected (98).
In brief, NGF is a basic polypeptide dimer that binds
to cell surface receptors in a specific and saturable fash-
ion. It canbe isolatedfrom avariety ofendocrine and ex-
ocrine sources, and the presence of NGF receptors has
been demonstratedin several, butnotall, human NBlines
(96,97,99,100). Within hoursfollowing NGF treatment of
some sensitive NB cells there is anincreaseinamino acid
uptake, protein synthesis, and neurite extension(99,101).
For example, after 5 days oftreating a cloned subline of
SK-N-SH designated by SY5Y, there is a 5-fold increase
inthe rate ofprotein synthesis andextensive neurite out-
growth (101,102). These neurites are capable offiring ac-
tionpotentials asjudgedby electrophysiologic andphar-
macologic criteria, whereas the undifferentiated
counterparts are not (103,104). In addition, the intracel-
lular stores ofmonoamines and levels ofneuron-specific
enolase increase, with associated increases in plasma
membrane restingpotentials(105). Some human NB cell
lines have also beenreportedtorespond to NGF with an
acceleratedrate ofattachmentto culture dishes(106). De-
spite theseobservations, responses to theeffects ofNGF
in many NB lines can only be considered to be feeble at
best(i.e., minimal neurite outgrowthwith sparse changes
in growth rate) (10,100).
From studies in other cell systems, it appears that
NGF'sbiological actions are nottriggered exclusivelyby
interactions with the cell surface receptor. Indeed, it has
been shownthat NGF or NGF andits internalized recep-
tor complex can interact with target cells at the level of
the cell membrane, cytoplasm, and nucleus, suggesting
that more than one type ofreceptor is involved in medi-
ating its actions (96). Consistent with this concept is the
observation that in the cultured pheochromocytoma cell
line PC12, which undergoes neuronlike differentiation,
NGF-stimulated neurite outgrowth requires both trans-
cription-dependent and independent pathways (107). As
suggested by Green and Shooter (96), it is possible that
transcription-dependent actions require internalization
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and interaction withnuclear receptors, whereas transcrip-
tion independent actions are triggered via cell-surface
receptors and second messengers.
Cyclic AMP (cAMP) is aputative second messenger for
ahost ofhormones and hasbeen implicated as mediating
some of the actions of NGF. However, the evidence for
cAMP acting as the sole second messenger is conflicting
(96). From studies on PC12 linesusingthe adenylate cy-
clase activator forskolin and chemically modified cAMP
analogues, it appears that NGF can act through cAMP-
independent pathways and that cAMP activation of pro-
tein kinases is neither necessary nor sufficient for NGF-
inducedneurite formation (108). Ithas alsobeen hypothe-
sized that NGF might exert its effects by primary regu-
lation ofionfluxes. Inthis connection, Boonstra et al. (109)
have shown that within minutes of treating PC12 cells
with NGF, there is stimulation of an amiloride-sensitive
electroneutral Nainflux system. However, prolonged in-
cubation of cells with amiloride failed to block NGF-
induced cellular differentiation. More recentlyit has been
shown that NGF induces electrical excitability in PC12
cells by augmentation of the membrane density of Na
channels, presumably by increasing the transcription of
Na channel genes (110,111). Although it could be specu-
lated that this action is a secondary effect ofthe differen-
tiation process, it has recently been shown that electrical
excitability can, by itself, influence neurite outgrowth
(112). As such, the causal relationship between NGF-
inducedchangesinionfluxes andneuronal differentiation
remains to be elucidated.
Butyric Acid
The natural four-carbon fatty acid, butyric acid, has
been studied as an inducer of differentiation in several
systems. For example, butyric acid treatment has been
reported to increase the production ofhumangonadotro-
pin in HeLaandhumanlungcarcinoma cells (113,114) and
human myelocytic leukemia cells cultured with this agent
have been shown to differentiate along the granulocytic
pathway (115). Prasad and co-workers (116,117) have
reported that butyrate at a concentration of 0.5 mM in-
duced both cell death and some neurite production in hu-
man NB celllines, whereas itreversibly inhibited prolifer-
ation without causing differentiation in murine NB cells.
In a neural crest-derived human retinoblastoma cell line,
butyrate treatment hasbeenreported toresultingrowth
inhibition aswell as aflatter-appearingmorphology (118).
The exactmechanism ofactionresponsible forthe effects
ofNabutyrate are unknown, although it is thought to in-
volve a direct action on the cell genome. In HeLa cells,
butyrate treatment results in an increase in the acetyla-
tion of histones H3 and H4 through an inhibition of the
deacetylating enzyme. The consequence of an increase in
acetylated histones includes alterations in chromatin
structure and function (119). In murine NB cells,
butyrates affect the synthesis andturnover ofhistone Hi
subtypes with an enrichment of subfraction H10 (120).
The significance of this observation is underscored by
reports that the state of histone acetylation can be cor-
related withthe transcriptional activity ofcertain genes
(121).
Polar-Planar Compounds
Low molecular weight polar-planar compunds such as
dimethyl sulfoxide (DMSO) and hexamethylene bisaceta-
mide (HMBA) constitute a class ofagents that has been
reported to induce differentiation ofvarious cell lines in
vitro, including NB (122). HMBA induces differentiation
in several leukemic lines, solid tumorlines, and some NB
celllines(122-126). The additionof2% DMSO to cultures
ofthe human NB cell line LAN-1 and themurine cellline
C-1300 resulted inmorphologic differentiation wihin36 hr
following addition ofthe agent and was accompanied by
a marked inhibition of cell multiplication and colony
growth (127). Interestingly, prior invitro treatment ofthe
murine cells with DMSO delayedbut did notprevent tu-
mor formation in nude mice and did not significantly
change animal survival. Similarly, there was no significant
effect on tumor growth or animal survival ifDMSO was
giveninvivofollowingthe inductionoftumors. Howthese
agents act in inducing differentiation in NB is subject to
speculation. However, from work in other cell systems
there is compelling evidence to suggest that DMSO and
HMBA cause asignificant decreaseinthe levels ofinositol
triphosphate and diacylglycerol(DAG)withina shorttime
of addition to culture (128). Since DAG activates PKC
(129), this implies that the effects of DMSO and HMBA
may be brought aboutbyperturbations in cell membrane
structure which in turn can inhibit PKC. Indeed, in leu-
kemic cell lines, DAG inhibits DMSO-induced differenti-
ation (130). However, inhibition of PKC alone cannot be
the sole initiator of differentiation since the phorbol
diester 12-0-tetradecancyl-phorbol-13-acetate, which ac-
tivates PKC (131), can also induce morphologic and bio-
chemical differentiation in some cells, including NB
(132-135). Further explorations in the actions of these
compounds on PKC activity in NB would be ofgreat in-
terest.
Cyclic AMP System
Therapidmodulation ofcAMPlevelsmakesthis second
messenger aprime candidate for influencing cellular pro-
cesses involving maturation and differentiation. That
cAMP was involved in cell growth and differentiation be-
came clear beginning in 1971 when two simultaneous
reports ofstudies with culturedmammalian cells demon-
strated an effect ofthis substance oninducingphenotypic
maturation (136,137). Since then, substantial experimen-
tal evidence has been accumulatedimplicating alterations
in cyclic nucleotide regulatory mechanisms as being im-
portant in the process of differentiation (76). With some
humanneuroblastomacelllines, anincrease inneurite ex-
tension and reduced growth rate can be demonstrated
when cAMP derivatives, agents that activate adenylate
cyclase or inhibit phosphodiesterase, are administered
singly or in combination (138,139). These observations,
alongwith dramaticphenotyic changes seen withmurine
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neuroblastoma cells (138), have prompted limited appli-
cation ofcAMP-elevating agentsforthe treatment ofthis
disease (140,141). In some reports, apparent beneficial
results were claimed as a result of promoting in vivo
maturation ofcancer cells (140,141). However, these cases
lacked objective standards of evaluation and to date no
rigorous trials have been published.
Cyclic AMP is thought to affect changes inmammalian
cells through the activation of one or both cAMP-
dependentprotein kinases (142). Twoforms ofthe kinases,
referred to as type I and II, havebeenidentified and are
composed ofthe same catalytic subunit with two differ-
ent regulatory subunits (RI and RII) (143). Activation of
the kinase system occurs when cAMPbinds to the RI or
RII subunit with release ofthe catalytic subunit, result-
ingin thephosphorylation ofvariousproteins(143). Omit-
ted from this highly simplified depiction are a host ofin-
teractions between the cAMP system, otherkinases, and
Ca(77). Although the role ofcAMPinregulating cell cyto-
solic pathways such as glycogenolysis have been well
described (77), the mechanisms underlying its effects on
cell differentiation remainobscure. Recentinvestigations
in cell lines other than NB have focused on interactions
between cAMP and oncogenes. Elevations in cAMPlevels
in HL-60 result in rapid (3 hr) decreases in c-myc RNA
levels preceding detectable changes in proliferation and
differentiation (144,145). In the NB cell line SMS-KAN,
a significant decrease in N-myc expression has been ob-
served following maximal morphologic differentiation in-
duced by dibutyryl cAMP(43). Hence, cAMPmayinduce
differentiation through a kinase-mediated modulation of
oncogene expression.
Conclusion
As amalignant tumor ofchildhood, neuroblastoma has
proven to be fascinatingfrom abiological aswell as clini-
cal viewpoint. Several agents have been reported to in-
duce in vitro differentiation ofNB into a variety ofcells
sharing a neural-crest lineage. Treatment with retinoids
has been shown to inhibit in vitro cell proliferation and
retard tumorgrowth innude mice, suggestingthatthese
agents may prove useful in the treatment ofmetastatic,
refractory disease.
The biochemical and ionic changes necessary forthe in-
duction ofdifferentiation in NB cells remains subject to
investigation. Aside from relying onmorphologic altera-
tions, early markers ofdifferentiation are being sought;
monitoring changes in oncogene products may serve such
a purpose. In so doing, the initial events triggering cell
maturation may be more amenable to study. In this con-
nection, modulation ofion channel function by a variety
of agents, which in turn can modulate gene expression,
promises tobe afruitful areato explore in NB. The study
ofNB promises to open new vistas in the analysis oftu-
morgrowthand differentiation andmayprovide clinicians
with potent chemotherapeutic agents capable ofaltering
the basic biology ofneoplasms.
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